AKBA Price Prediction, Akebia Therapeutics AI Recommendations

AKBA sees MACD Histogram just turned negative

AKBA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on March 09, 2023. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 48 instances where the indicator turned negative. In 42 of the 48 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 88%.

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 10, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on AKBA as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

AKBA moved below its 50-day moving average on March 13, 2023 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for AKBA crossed bearishly below the 50-day moving average on March 20, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKBA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AKBA advanced for three days, in of 255 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AKBA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.937) is normal, around the industry mean (21.930). P/E Ratio (0.000) is within average values for comparable stocks, (123.806). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.812). Dividend Yield (0.000) settles around the average of (0.028) among similar stocks. P/S Ratio (0.410) is also within normal values, averaging (302.440).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

AKBA is expected to report earnings to rise 200.00% to -11 cents per share on May 08

Q1'23

Est.

$-0.12

Q4'22

Beat

by $0.14

Q3'22

Missed

by $0.11

Q2'22

Beat

by $0.47

Q1'22

Missed

by $0.06